Coherus Oncology, Inc. Announces Change in Independent Auditor
REDWOOD CITY, CA, June 15, 2026 – Coherus Oncology, Inc. (NASDAQ: CHRS), a leading company in the development and commercialization of biological products, has announced a significant change in its independent registered public accounting firm. This change was formalized by the Audit Committee of the Board of Directors on June 12, 2026.
Key Points from the Report
- Dismissal of Ernst & Young LLP (EY): The Audit Committee has dismissed Ernst & Young LLP as the company’s independent registered public accounting firm, effective June 12, 2026.
- Appointment of PricewaterhouseCoopers LLP (PwC): PwC has been selected as the new independent registered public accounting firm for the fiscal year ending December 31, 2026, subject to standard client acceptance procedures.
- Financial Statement Opinions: EY’s reports for the fiscal years ended December 31, 2025 and 2024 did not contain any adverse opinions, disclaimers, or qualifications regarding uncertainty, audit scope, or accounting principles.
- No Disagreements or Unresolved Issues: There were no disagreements with EY on any matters of accounting principles or practices, financial statement disclosure, or auditing scope or procedures during the relevant periods.
- Material Weakness Remediation: A previously reported material weakness in internal controls over financial reporting (related to documentation and review of certain inventory account reconciliations) was identified in the company’s Annual Report for the year ended December 31, 2024. Management reported that this weakness had been remediated by the end of 2025 and internal controls were deemed effective as of December 31, 2025.
- EY’s Confirmation: EY has provided a letter to the Securities and Exchange Commission confirming its agreement with the statements made by the company regarding the change in auditors and the absence of unresolved matters.
Important Shareholder Information
- Potential Share Price Impact: Changes in a company’s independent auditor, especially to another “Big Four” firm like PwC, are often scrutinized by investors and analysts. While the company reports no disagreements or adverse opinions, such changes can sometimes raise questions about future financial reporting, audit scope, or accounting practices.
- Internal Controls: The remediation of the previously reported material weakness in internal control over financial reporting should be reassuring to shareholders, as ongoing material weaknesses often raise red flags for investors and regulators.
- Regulatory Compliance: The company has followed all required procedures, including obtaining a letter from EY and providing full disclosure in the Form 8-K filing.
- Exhibit Filed: The company has included as an exhibit the letter from EY dated June 15, 2026, confirming the firm’s agreement with the company’s disclosures.
Details for Investors
Coherus Oncology, Inc. is registered under the ticker CHRS on the Nasdaq Global Market. The company’s principal business address is 333 Twin Dolphin Dr, Suite 600, Redwood City, CA 94065. The company is incorporated in Delaware and is not designated as an emerging growth company under SEC definitions.
This change in auditor comes after several years of continuity with EY and at a time when the company has reported effective remediation of previous internal control issues. There is no indication of disagreements, and the transition to PwC appears to be a proactive, strategic decision by the Audit Committee.
For a full copy of the letter from Ernst & Young LLP to the SEC, shareholders can refer to Exhibit 16.1 in the company’s latest Form 8-K filing.
Conclusion
While changes in auditing firms are not uncommon, they are watched closely by the market. The absence of unresolved issues or negative opinions from EY, coupled with the remediation of prior internal control weaknesses, should provide a degree of reassurance to investors. Nonetheless, shareholders are encouraged to monitor future filings for any further developments or disclosures related to this transition.
Disclaimer: This article is based on publicly available filings of Coherus Oncology, Inc. and is intended for informational purposes only. It does not constitute investment advice. Investors should perform their own due diligence or consult with a financial advisor before making investment decisions. The author and publisher are not responsible for any actions taken based on the information contained herein.
